Results 81 to 90 of about 12,266 (204)

Beyond PD‐1: Mechanisms of Resistance to Checkpoint Blockade in Classical Hodgkin Lymphoma and Next‐Generation Immune Strategies

European Journal of Haematology, EarlyView.
ABSTRACT PD‐1 inhibitors have reshaped the treatment landscape of classical Hodgkin lymphoma, yet a substantial proportion of patients exhibit primary or acquired resistance driven by tumor‐intrinsic alterations, immunosuppressive microenvironmental signals, metabolic constraints, and EBV‐mediated modulation.
Santino Caserta, Enrica Antonia Martino, Mamdouh Skafi, Maria Eugenia Alvaro, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

Membrane-Mediated Action of Phosphodiesterase 5 Inhibitors

Pharmaceutics
Background/Objectives: Phosphodiesterase 5 (PDE5) inhibitors, sildenafil, vardenafil, and tadalafil, activate the cyclic guanosine monophosphate pathway resulting in vascular smooth muscle relaxation.
Anna I. Malykhina, Svetlana S. Efimova, Olga S. Ostroumova   +2 more
doaj   +1 more source

Suppression of premature ventricular complexes with the PDE5 inhibitor sildenafil: First clinical experience

Experimental Physiology, EarlyView.
Abstract The phosphodiesterase‐5 inhibitor sildenafil suppresses ventricular arrhythmias in a sheep model of drug‐induced long QT. In that study, ventricular arrhythmias were abolished by reducing premature ventricular complexes (PVCs) and delaying PVC onset, thus preventing ‘R‐on‐T’ ventricular tachycardia.
David C. Hutchings, Christopher P. Denton, Luigi Venetucci, Andrew W. Trafford   +3 more
wiley   +1 more source

Clinical and preclinical treatment of urologic diseases with phosphodiesterase isoenzymes 5 inhibitors: an update

Asian Journal of Andrology, 2016
Phosphodiesterase isoenzymes 5 inhibitors (PDE5-Is) are the first-line therapy for erectile dysfunction (ED). The constant discoveries of nitric oxide (NO)/cyclic guanosine monophosphate (cGMP) cell-signaling pathway for smooth muscle (SM) control in ...
Wen-Hao Zhang, Xin-Hua Zhang
doaj   +1 more source

Influence of sildenafil on blood oxygen saturation of the obstructed bladder [PDF]

, 2014
Background: Blood oxygen saturation (BOS) is decreased in a low-compliant, overactive obstructed bladder. The objective of this study is to determine the effect of Sildenafil (SC) on bladder function and BOS) in an in vivo animal model of bladder outlet ...
Amelink, A. (Arjen), Kok, D.J. (Dirk), Scheepe, J.R. (Jeroen), Wolffenbuttel, K.P. (Katja)   +3 more
core   +2 more sources

Non-invasive management of primary phosphodiesterase type 5 inhibitor failure in patients with erectile dysfunction

Therapeutic Advances in Urology, 2009
Phosphodiesterase type 5 inhibitors (PDE5-i) have become first line therapy for the treatment of erectile dysfunction. Most initial prescriptions for PDE5-i are by primary care practitioners.
Gregory Lowe MD, Robert Bahnson
doaj   +1 more source

Adherence to Phosphodiesterase Type 5 Inhibitors in the Treatment of Erectile Dysfunction in Long-Term Users: How Do Men Use the Inhibitors?

Sexual Medicine, 2014
Introduction: The high effectiveness of phosphodiesterase type 5 inhibitors (PDE5-i) in the treatment of erectile dysfunction (ED) has been demonstrated. However, previous research shows that PDE5-i treatments have high discontinuation rates.
Ana Carvalheira, PhD, Vera Forjaz, MSc, Nuno Monteiro Pereira, MD, PhD   +2 more
doaj   +1 more source

Sex differences in pulmonary vascular control: focus on the nitric oxide pathway [PDF]

, 2017
Although the incidence of pulmonary hypertension is higher in females, the severity and prognosis of pulmonary vascular disease in both neonates and adults have been shown to be worse in male subjects. Studies of sex differences in pulmonary hypertension
Danser, A.H.J. (Jan), Duncker, D.J.G.M. (Dirk), Merkus, D. (Daphne), Reiss, I.K.M. (Irwin), Wijs-Meijler, D.P.M. (Daphne) de   +4 more
core   +1 more source

Outcomes of Aquablation in BPH with bladder stones: Analysis of the ICARUS database

BJUI Compass, Volume 7, Issue 2, February 2026.
Abstract Objective The purpose of this study is investigate the clinical outcomes of men with benign prostatic hyperplasia (BPH) and bladder stones treated concomitantly with Aquablation and bladder stone removal in an international, multi‐institutional cohort.
Joshua D. Cabral, Margaret Gannon, Gregory Raster, David J. Nusbaum, David Bouhadana, Adel Arezki, Aalya Hamouda, Anouk Leathead, Ilan Ohana, Rosie Foucault, Iman Sadri, Jeffrey A. Sioufi, Nick Lee, Tarek Benzouak, Liam Murad, Nicholas J. Corsi, John Klein, Inderjit Singh, James Kearns, Cecilia Chang, Juan Justo Quintas, Kevin C. Zorn, Tiago Rodrigues, Shawn H. Marhamati, Brian T. Helfand, Alexander P. Glaser   +25 more
wiley   +1 more source

The effect of phosphodiesterase-5 inhibitors on cerebral blood flow in humans: A systematic review. [PDF]

, 2017
Agents that augment cerebral blood flow (CBF) could be potential treatments for vascular cognitive impairment. Phosphodiesterase-5 inhibitors are vasodilating drugs established in the treatment of erectile dysfunction (ED) and pulmonary hypertension.
Barrick, TR, Hainsworth, AH, Isaacs, JD, Kruuse, C, Madigan, JB, Moynihan, B, Pauls, MM   +6 more
core   +1 more source